Aurinia Pharmaceuticals Inc. AUPH
Aurinia Pharmaceuticals Inc. (Nasdaq: AUPH) is an immunology/inflammation drug developer. Its lead program, aritinercept, is in Phase 1 for autoimmune diseases. Its next catalyst on record is PRESERVE (LUPKYNIS combination therapy): Primary endpoint: proportion of patients achieving complete renal response at 6 months (date not stated).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: PRESERVE (LUPKYNIS combination therapy) — Primary endpoint: proportion of patients achieving complete renal response at 6 months (date not stated). 1 catalyst on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| LUPKYNIS (voclosporin) | active lupus nephritis | small molecule | Approved |
| aritinercept | autoimmune diseases (four potential indications) | protein/peptide | Phase 1 |
| LUPKYNIS + belimumab/obinutuzumab/anifrolumab (PRESERVE study) | lupus nephritis | small molecule | PHASE_4 |
Recent results and decisions
- Oct 30, 2026started Aurinia initiated PRESERVE, a Phase 4 study investigating LUPKYNIS in combination with belimumab, obinutuzumab or anifrolumab in patients with lupus nephritis.
Aurinia has recently initiated PRESERVE, a Phase 4, multicenter study investigating the combination of LUPKYNIS and belimumab, obinutuzumab or anifrolumab in patients with lupus nephritis.
Filing - Oct 30, 2026started Aurinia has initiated clinical development of aritinercept in four potential indications.
Aurinia has now initiated clinical development of aritinercept in four potential indications.
Filing
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 1 immunology/inflammation companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.